GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty to look forward to, CEO Andrew Witty reminded them on Thursday.
GlaxoSmithKline rolled out data from a hefty Phase III study showing that its shingles-fighting candidate cut the risk of that disease by 97.2% in adults aged 50 and older, compared with placebo.
More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.
GlaxoSmithKline got some good news for its big vaccines group, scoring a pivotal Phase III win for its shingles vaccine HZ/su more than four years after the study was launched.
A team from Finland has for the first time confirmed a link between GlaxoSmithKline's swine flu vaccine, Pandemrix, and narcolepsy.
The flu season's most common viral strain has mutated, meaning this year's shots may not fully protect against it. But the so-called "drifted" strain may open up an opportunity for antiviral makers like Roche's Genentech and GlaxoSmithKline, with the CDC urging earlier use of anti-flu drugs to combat potentially severe symptoms.
SetPoint Medical is starting a clinical trial to treat Crohn's disease patients with its implantable neuromodulation device. The startup previously reported a positive pilot study of the device to treat rheumatoid arthritis.
GlaxoSmithKline has long weighed a sale of some of its established drugs, planning to hive off $3 billion worth of older products to slim down its sagging portfolio and make room for fast-growing drugs. Now the company is changing its tune, announcing today that it will hold on to its aging products.
Even after going off patent in some markets, the sophisticated inhaler device for GlaxoSmithKline's Advair made it difficult to copy, protecting sales of the asthma drug. But with copies and competition now eating away market share, and payers demanding deep discounts, what Advair is giving GSK is grief, including the loss of at least 900 sales and research jobs in the U.S.
The company says that the bulk of the job cuts will be made in Research Triangle Park, NC, slashing R&D as it concentrates drug research work in Philadelphia and Stevenage in the U.K.